[HTML][HTML] Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
MZ Wojtukiewicz, MM Rek, K Karpowicz… - Cancer and Metastasis …, 2021 - Springer
The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
B Coiffier, C Sarkozy - Hematology 2014, the American Society …, 2016 - ashpublications.org
Although rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …
CHOP) is the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL),∼ …
[HTML][HTML] CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via …
YH Huang, K Cai, PP Xu, L Wang, CX Huang… - … and Targeted Therapy, 2021 - nature.com
Epigenetic alterations play an important role in tumor progression of diffuse large B-cell
lymphoma (DLBCL). However, the biological relevance of epigenetic gene mutations on …
lymphoma (DLBCL). However, the biological relevance of epigenetic gene mutations on …
Structural basis for potency and promiscuity in poly (ADP-ribose) polymerase (PARP) and tankyrase inhibitors
AG Thorsell, T Ekblad, T Karlberg… - Journal of medicinal …, 2017 - ACS Publications
Selective inhibitors could help unveil the mechanisms by which inhibition of poly (ADP-
ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 …
ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 …
CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies
Purpose: Despite promising clinical activity, T-cell–engaging therapies including T-cell
bispecific antibodies (TCB) are associated with severe side effects requiring the use of step …
bispecific antibodies (TCB) are associated with severe side effects requiring the use of step …
Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network
C Laurent, M Baron, N Amara, C Haioun… - Journal of clinical …, 2017 - ascopubs.org
Purpose To prospectively assess the clinical impact of expert review of lymphoma diagnosis
in France. Materials and Methods From January 2010 to December 2013, 42,145 samples …
in France. Materials and Methods From January 2010 to December 2013, 42,145 samples …
[HTML][HTML] Genetic and epigenetic determinants of diffuse large B-cell lymphoma
TJ Bakhshi, PT Georgel - Blood cancer journal, 2020 - nature.com
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is
notorious for its heterogeneity, aggressive nature, and the frequent development of …
notorious for its heterogeneity, aggressive nature, and the frequent development of …
[HTML][HTML] Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity
NJ Curtis, L Mooney, L Hopcroft, F Michopoulos… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Tumors frequently display a glycolytic phenotype with increased flux through glycolysis and
concomitant synthesis of lactate. To maintain glycolytic flux and prevent intracellular …
concomitant synthesis of lactate. To maintain glycolytic flux and prevent intracellular …
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
E Van Den Neste, N Schmitz, N Mounier… - Bone marrow …, 2017 - nature.com
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma
(DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of …
(DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of …
A review of autologous stem cell transplantation in lymphoma
Abstract Purpose of Review Chemotherapy remains the first-line therapy for aggressive
lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15 …
lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15 …